A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

NCT02092922 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Multiple Myeloma

Interventions

DRUG: Filanesib, KSP (Eg5) inhibitor; intravenous
DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Sponsor

Pfizer